About Contact Us Careers

Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market Size and Forecast, by Therapy Type (Chemotherapy, Immunotherapy, Radiotherapy, Hormonal Therapy), Application (General Medical & Surgical Hospitals, Specialty Hospitals, Clinics) - Growth Trends, Key Players, Regional Analysis 2026-2035

  • Report ID: 2884
  • Published Date: Nov 19, 2025
  • Report Format: PDF, PPT

Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market Outlook:

Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market size was over USD 8.28 billion in 2025 and is anticipated to cross USD 13.23 billion by 2035, witnessing more than 4.8% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of non-metastatic castration resistant prostate cancer treatment is estimated at USD 8.64 billion.

Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market Size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

The growth of the market can be attributed to the increasing geriatric population and the rising prevalence of non-metastatic castration-resistant prostate cancer amongst individuals on a global level. People above 50 have a higher chance to be diagnosed with nmCRPC, therefore, the surge in the geriatric population is anticipated to be one of the major growth factors of the market. According to the data collected by the National Cancer Institute of the U.S. Department of Health and Human Services, in 2020, the estimated new cases and the number of deaths from prostate cancer in the U.S. were 191,930 and 33,330, respectively.

In addition to these, global non-metastatic castration resistant prostate cancer (NMcrpc) market trends such as Extensive research associated with cancer treatment in western countries, along with the growing investment in the development of advanced therapies are expected to fuel the progress of the market during the forecast period. People nowadays are more aware of early diagnosis of cancer owing to the surge in awareness and launch of the various government program to promote the treatment of cancer. For instance, in India government programs such as Health Minister’s Cancer Patient Fund, National Health Protection Scheme, and others are observed to be quite beneficial to get cancer treatment. Hence, all these factors are anticipated to influence the market growth over the forecast period.

Key Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market Insights Summary:

  • Regional Highlights:

    • By 2035, North America is anticipated to command a 30% share of the non-metastatic castration sesistant prostate cancer (nmCRPC) treatment market, owing to increasing awareness about nmCRPC and the need for innovative cancer treatment solutions.
    • Europe is projected to secure the second-largest share by 2035, attributed to its proven success in drug development and the high incidence of prostate cancer in the region.

  • Segment Insights:

    • The hormonal therapy segment of the non-metastatic castration sesistant prostate cancer (nmCRPC) treatment market is projected to hold the largest share by 2035, propelled by higher positive diagnosis rates and superior treatment efficiency compared to chemotherapy.
    • The specialty hospitals segment is expected to dominate the market by 2035, supported by the increasing preference for healthcare facilities specializing in nmCRPC treatment.

  • Key Growth Trends:

    • Growing Prevalence of Prostate Cancer
    • Rising Geriatric Population Across the Globe

  • Major Challenges:

    • Expensive nmCRPC Treatment Therapies
    • Lack of Awareness About the Disease in Lower Economic Regions

  • Key Players: Pfizer Inc., Astellas Pharma Inc., Clovis Oncology, Inc., Johnson & Johnson Health Care Systems Inc., Bayer AG, Orion Corporation, Merck & Co., Inc., Novartis AG, AstraZeneca PLC.

Global Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market Forecast and Regional Outlook:

  • Market Size & Growth Projections:

    • 2025 Market Size: USD 8.28 billion
    • 2026 Market Size: USD 8.64 billion
    • Projected Market Size: USD 13.23 billion by 2035
    • Growth Forecasts: 4.8%

  • Key Regional Dynamics:

    • Largest Region: North America (30% Share by 2035)
    • Fastest Growing Region: Europe
    • Dominating Countries: United States, Germany, United Kingdom, France, Japan
    • Emerging Countries: China, India, South Korea, Brazil, Australia

    • Last updated on : 19 November, 2025

Growth Drivers

  • Growing Prevalence of Prostate Cancer – the main cause of prostate cancer is still not known, although aging can be a major factor in this disease. Additionally, ethnic group factor has also been noticed where black men were more likely to get prostate cancer than Asian men. For instance, it was estimated that around 100 new cases of prostate cancer are diagnosed every year per 100,000 men across the globe.

  • Rising Geriatric Population Across the Globe – growth in the geriatric population is expected to be one of the major factors to boost the market growth over the forecast period since it has been noticed by medical professionals that the chances of prostate cancer are much higher in men above 50. For instance, data represented by the World Bank, it was stated that in 2021, the global geriatric population reached 758,631,369 which was an increase from 737,138,709 in 2020.

  • Increasing Instances of Other Types of Cancer - non-metastatic castration-resistant prostate cancer (nmCRPC) treatment methods are also utilized to treat other types of cancers as well such as breast, lung, skin, and other cancer. Cancer has been considered to be the leading cause of death across the globe. The prevalence of cancer is presented by incidents and survival rate. For instance, in women, the prevalence of breast cancer was high in women reaching approximately 42% while in men, prostate cancer was observed to be most prevalent reaching approximately 43% in 2019.

  • Growth in the Investment and R&D Activities in the Oncology Segment – owing to the escalating prevalence of cancer around the world, a surge in R&D activities to find cures for cancer can be observed. As of 2021, global cancer research and development activities were estimated to grow by 50%.

  • Rising Development of New Drugs and Biomarkers – the utilization of biomarkers is noticed to be very high in clinical trials where approximately 50% of the clinical trials used biomarkers in 2018.

Challenges

  • Expensive nmCRPC Treatment Therapies

The non-metastatic castration-resistant prostate cancer treatment is expected to be very expensive since depending on the type and its stage, healthcare providers give various types of therapy such as particle therapy, brachytherapy, chemotherapy, hormonal therapy, radiosurgery, and others.All of them require plenty of money and it also increases based on the duration of treatment. Hence, this factor is expected to limit the growth of the market over the forecast period.

  • Lack of Awareness About the Disease in Lower Economic Regions
  • Lack of Skilled Medical Professionals

Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Year

2026-2035

CAGR

4.8%

Base Year Market Size (2025)

USD 8.28 billion

Forecast Year Market Size (2035)

USD 13.23 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market Segmentation:

Therapy Type Segment Analysis

The global non-metastatic castration resistant prostate cancer (nmCRPC) treatment market is segmented and analyzed for demand and supply by therapy type into chemotherapy, immunotherapy, radiotherapy, hormonal therapy, and others. Out of these types, the hormonal therapy segment is estimated to gain the largest market share in the year 2035. The growth of the segment can be attributed to the higher positive diagnosis rates and better efficiency of hormonal therapy than chemotherapy. Moreover, hormonal therapy is widely being used as an adjuvant treatment alongside radiation therapy and surgery, which is also projected to contribute to the growth of the segment during the forecast period. hormonal therapy has been observed to be the most effective method to stop or slow down the growth of cancer, especially, prostate and breast cancer since these types of cancers use hormones to grow. Hence, the higher prevalence of breast cancer is further expected to hike the segment growth over the forecast period. For instance, as of 2020, nearly 650,000 women lost their lives owing to breast cancer across the globe.

Application Segment Analysis

The global non-metastatic castration resistant prostate cancer (nmCRPC) treatment market is also segmented and analyzed for demand and supply by application into general medical & surgical hospitals, specialty hospitals, clinics, and others. The specialty hospitals segment is expected to lead the market over the forecast period. The growth of the segment can be attributed to the fact that nmCRPC is a relatively rare occurrence and as a result, a considerable portion of the population with this cancer on a global level tends to choose healthcare facilities specializing in its treatment. Since specialty is known to target one specific area of care and medicine and these hospitals are generally owned by physicians themselves. Specialty hospitals include cardiac facilities, orthopedic centers, and surgical centers. Hence, these are the hospital devoted to specialized care, enhanced and treatment of long-term illness, injury, cancer diagnostics, and infirmity. For instance, in the United States, the specialty hospital industry is anticipated to grow by approximately 2% in 2023 which sums up to around USD 60 billion. Hence, all these factors are projected to hike the market growth over the forecast period.

Our in-depth analysis of the global market includes the following segments:

          By Therapy Type
  • Chemotherapy
  • Immunotherapy
  • Radiotherapy
  • Hormonal Therapy
  • Others

 

            By Application
  • General Medical & Surgical Hospitals
  • Specialty Hospitals
  • Clinics
  • Others
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market - Regional Analysis

North American Market Insights

North America industry is anticipated to dominate majority revenue share of 30% by 2035, The growth of the market can be attributed majorly to the increasing awareness about nmCRPC and the need to develop innovative cancer treatment solutions in the region. Furthermore, in 2021, the market in North America was expected to hold the largest share in terms of revenue, owing to the growing investment of governmental and non-governmental agencies in cancer screening & research, accompanied by the presence of leading healthcare service providers in the region. Along with this, North America also leads in terms of ongoing clinical trials, which is also expected to contribute to the market growth in the region. North America is known to be the most prevalent region of cancer. For instance, as of 2018, out of 1 million cancer cases, around 12% of them were projected to be prostate cancer in North America. 

Europe Market Insights

The European non-metastatic castration resistant prostate cancer (nmCRPC) treatment market, amongst the market in all the other regions, is projected to hold the second largest share during the forecast period. the market in Europe is also anticipated to occupy a significant share in the mnCRPC treatment market on account of its proven success in terms of drug development and the high incidence of prostate cancer in the region. As per the analysis of the European Commission, prostate cancer is ranked first among the most widely diagnosed cancer among men in the European Union. For instance, it was estimated that approximately 50,000 new prostate cancer are diagnosed in the United Kingdom every year which sums up to 135 cases every day. Apart from that, nearly 12,000 people died owing to prostate cancer in the region between 2017-2029. Hence, all these statistics about prostate cancer are estimated to expand the market size over the forecast period.

Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market Players:

    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Astellas Pharma Inc.
    • Clovis Oncology, Inc.
    • Johnson & Johnson Health Care Systems Inc.
    • Bayer AG
    • Orion Corporation
    • Merck & Co., Inc.
    • Novartis AG
    • AstraZeneca PLC

Recent Developments

  • Astellas Pharma Inc. to conduct clinical trials to develop cell therapy. The development pipeline of the company includes high unmet medical needs such as autoimmune & cardiovascular diseases and cancer. The cell therapy research of the company is based on pluripotent stem cells (PSC)

  • Clovis Oncology, Inc. to present data from Phase 3 trial, “TRITON3: A Phase 3 Study of Rucaparib vs. Physician’s Choice of Therapy inmCRPC Associated with Homologous Recombination Deficiency (HRD)”. The trial is associated with men with metastatic castration-resistant prostate cancer.

  • Report ID: 2884
  • Published Date: Nov 19, 2025
  • Report Format: PDF, PPT
  • Explore a preview of key market trends and insights
  • Review sample data tables and segment breakdowns
  • Experience the quality of our visual data representations
  • Evaluate our report structure and research methodology
  • Get a glimpse of competitive landscape analysis
  • Understand how regional forecasts are presented
  • Assess the depth of company profiling and benchmarking
  • Preview how actionable insights can support your strategy

Explore real data and analysis

Download Free Sample Report

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of non-metastatic castration resistant prostate cancer treatment is estimated at USD 8.64 billion.

The global non-metastatic castration resistant prostate cancer treatment market size was over USD 8.28 billion in 2025 and is anticipated to witness a CAGR of around 4.8%, crossing USD 13.23 billion revenue by 2035.

North America is anticipated to command a 30% share of the market, owing to increasing awareness about nmCRPC and the need for innovative cancer treatment solutions.

Key players in the market include Pfizer Inc., Astellas Pharma Inc., Clovis Oncology, Inc., Johnson & Johnson Health Care Systems Inc., Bayer AG, Orion Corporation, Merck & Co., Inc., Novartis AG, AstraZeneca PLC.

Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos